Location of Repository

Characteristics of Prediabetes, predictors of progression and strategies to prevent Type 2 Diabetes Mellitus in a multiethnic population in the United Kingdom

By Balasubramanian Thiagarajan Srinivasan


Executive Summary: Type 2 Diabetes Mellitus (T2DM) is a chronic multi factorial disorder linked to obesity that is associated with increased morbidity and mortality. T2DM poses a major public health problem with the prevalence expecting to reach 4 million in the United Kingdom by the year 2025.\ud Upto 50% of people may have established complications at the time of diagnosis of T2DM. However, T2DM is preceded by a latent phase of Prediabetes (PDM) which provides a window of opportunity for primary prevention. PDM is often known as impaired glucose metabolism (IGM) or impaired glucose regulation (IGR). PDM is a collective term for impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and those with combined IFG and IGT. The reported prevalence of these conditions is variable throughout the world. This thesis seeks to address key questions on identification of IGR, determine factors predicting progression to T2DM and thus propose prevention strategies in a mixed ethnic population in the UK using data from the ADDITION Leicester and ADDITION PLUS studies.\ud ADDITION Leicester is a sub study of the multinational multi centre study-ADDITION Europe. ADDITION study is a randomised controlled trial evaluating the benefits of a multi factorial cardiovascular disease risk factor intervention in a cohort of patients with screen detected T2DM.\ud The prevalence of PDM was 16% in the study population with IFG, IGT and combined IFG and IGT being 2.8%, 11% and 2.2% respectively. People of South Asian (SA) origin have a significantly higher adjusted prevalence of PDM compared to those of White European (WE) origin (OR: 1.57; 95% CI: 1.24 to 1.98). A risk score tailored to the local population (Leicester risk assessment score) was robust in identifying those at risk of developing T2DM and PDM as well those progressing from PDM to T2DM at 12 months. Subjects with PDM have a unique phenotype placing their cardiovascular disease (CVD) risks between T2DM and normal glucose tolerance. Novel markers of CVD such as Interleukin 6, Adiponectin, Leptin and C-reactive protein are also raised in those with PDM compared to normal.\ud The risk of progression from PDM to T2DM at 12 months is higher for SA compared to WE (OR: 3.09, 95% CI- 1.58 to 6.02). The diabetes progression rate (cases/100 person-years) for IFG, IGT and combined IFG and IGT were 5.51, 3.13 and 14.46 respectively. The risk of progression for SA people occurs at a lower cut off for BMI and waist circumference. A meta analysis of 13,314 patients from 22 studies with PDM revealed a pooled progression rate (cases per 100 person-years) (95% CI) to be 6.29 (4.29- 9.22), 7.48 (5.00-11.18) and 7.86 (5.51- 11.20) for people with IFG, IGT and combined IFG+IGT respectively.\ud Presence of CVD, central obesity measured both by waist circumference and BMI, triglycerides, fasting plasma glucose (FPG) and HbA1c significantly predict progression to T2DM at 12 months. Presence of metabolic syndrome with more than 2 additional criteria significantly predicts progression to T2DM. In terms of adipocytokines, TNFα is the only marker, after adjusting for confounders that is significantly associated with progression to T2DM. In terms of follow up of this cohort, we propose a two step method using FPG >6 mmol/L as a screening tool to identify people who can subsequently be screened using an OGTT, reducing the number of OGTT needed to 23.5%.\ud Our findings suggest using a structured screening programme with a risk score used in parallel to the recommended opportunistic screening for T2DM. The need for ethnic specific cut-off for obesity has been established. Factors such as presence of metabolic syndrome, HbA1c >6%, presence of a single diabetes range glucose value and pre-existing CVD may be used in risk stratification of individuals with PDM. These factors may also be used to guide those who may benefit from Metformin in addition to established life style interventions for PDM. Our findings provide a contemporary and prospective data on the prevalence of PDM in a multi ethnic UK population and factors predicting progression from PDM to T2DM.\ud A robust strategy using a self assessed risk score is proposed to identify those at risk of developing PDM and T2DM. A step wise ethnic specific algorithm using anthropometric measures is also recommended to enable follow up of those with PDM.\ud These findings have important implications for public health in informing strategies to address the emerging pandemic of T2DM

Publisher: University of Leicester
Year: 2011
OAI identifier: oai:lra.le.ac.uk:2381/9628

Suggested articles



  1. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes.
  2. (2006). A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed.
  3. (2000). A et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
  4. (2001). A et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study.
  5. A Markov chain model to assess the efficacy of screening for non- insulin dependent diabetes mellitus
  6. (1993). A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabet Med
  7. (1988). A quantitative approach to research integration.
  8. (2005). Adipokines: molecular links between obesity and atheroslcerosis.
  9. (2003). Adiponectin and protection against type 2 diabetes mellitus. Lancet
  10. (2006). Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose.
  11. (2004). Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes
  12. (2009). Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes
  13. (2004). Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men.
  14. (1991). Age as independent determinant of glucose tolerance. Diabetes
  15. (2003). Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care
  16. (2003). Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care
  17. (1997). American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care
  18. (2002). among individuals with a non-diabetic fasting glucose value. The San Antonio Heart study. Diabetes
  19. (1992). Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care
  20. (2000). Applied Logistic Regression.
  21. (2002). Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care
  22. (2003). Area based deprivation measures: A
  23. (2002). Arterial stiffness and insulin resistance. Semin Vasc Med
  24. (2006). Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus.
  25. (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials
  26. (2006). Association of acute-phase reactants with arterial stiffness in patients with type 2 diabetes mellitus. Clin Chim Acta
  27. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities
  28. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study.
  29. (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study.
  30. (2004). Association. Screening for Type 2 Diabetes. Diabetes Care
  31. (1995). Asymptomatic hyperglycemia is associated with increased intimal plus medial thickness of the carotid artery.
  32. (1999). Atherosclerosis--an inflammatory disease.
  33. (1988). Banting lecture 1988. Role of insulin resistance in human disease. Diabetes
  34. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ
  35. (1998). Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile. Diabetes
  36. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
  37. (2003). C-reactive protein predicts the deterioration of glycemia in chinese subjects with impaired glucose tolerance. Diabetes Care 26(8):2323-8,
  38. (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA
  39. (1991). Cardiovascular - Disease risk profiles.
  40. (2004). Cardiovascular risk associated with the metabolic syndrome.
  41. (1999). Changing glomerular filtration with progression from impaired glucose tolerance to Type II diabetes mellitus. Diabetologia
  42. (2000). Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation
  43. (2009). Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care
  44. (1998). Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care
  45. (1997). Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study.
  46. (2007). Communities and Local Government. The English indices of deprivation
  47. (1993). Community screening for noninsulin-dependent diabetes mellitus: self-testing for post-prandial glycosuria.
  48. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics
  49. (1998). Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. Diabetologia
  50. (1997). Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care
  51. (1990). Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes-Res
  52. (1999). Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care
  53. (2009). Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia
  54. (2003). Contributions of beta-cell factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 26(3):868-74,
  55. (2004). Cost-effectiveness studies of diabetes prevention in high-risk patients.
  56. (2001). Costeffectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type
  57. (2004). Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396-1402. Diabetologia
  58. (1991). Decline in incidence of epidemic glucose intolerance in Nauruans: implications for the "thrifty genotype".
  59. (2003). Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care
  60. (2006). Definition and diagnosis of Diabetes melitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation.
  61. (2003). delaying, or masking type 2 diabetes with metformin in the Diabetes Prevention Program? [10] (multiple letters).
  62. (2005). Derivation and validation of diabetes risk score for urban Asian Indians. Diabetes Res Clin Pract
  63. (2008). design and baseline data from the Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: a randomized controlled trial. Patient Educ Couns
  64. (2008). Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategy. Diabetes Obes Metab
  65. (1996). Developing a training programme in patient-centred consulting for evaluation in a randomised controlled trial; diabetes care from diagnosis in British primary care. Patient Educ Couns
  66. (2007). Development of evidence synthesis methods for health policy decision making - a chain of evidence approach.
  67. (1995). Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes
  68. (1979). Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care
  69. (2008). Diabetes and other disorders of glycemia in a rural South African community: prevalence and associated risk factors. Diabetes Care
  70. (1990). Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev
  71. (2000). Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev
  72. (2010). Diabetes Risk Score.
  73. (2001). Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care
  74. (2009). Diabetes UK and South Asian Health Foundation recommendations on diabetes research priorities for British South Asians. Khunti
  75. (1971). Diabetic glomerulosclerosis in the absence of glucose intolerance. Ann Intern Med
  76. (2005). Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose.
  77. (2008). Diagnostic value of glycated haemoglobin HbA(1c) for the early detection of diabetes in high-risk subjects. Diabet Med
  78. (1999). Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension
  79. Do Glucose indices independently correlate with Pulse Wave Velocity, a surrogate of atherosclerosis? Diabetes 2008; 57(Suppl 1):A182.
  80. (2007). Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve
  81. (2008). Does screening work for the common good? ADDITION - Leicester: design of a multi-factorial intervention trial in an ethnically diverse population with screendetected type 2 diabetes. Diabetologia
  82. (1995). Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats.
  83. (1997). Effect of deprivation on general practitioners referral rates. Jarman score measures workload not deprivation.
  84. (2004). Effect of exercise training in patients with impaired glucose tolerance: 5 year follow-up.
  85. (1998). Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet
  86. (1989). Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans.
  87. Effect of medicine and non medicine interventions on outcomes of patients with impaired glucose tolerance: 5 year follow-up.
  88. (2006). Effect of ramipril on the incidence of diabetes.
  89. (2002). Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation
  90. (2009). Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. Diabetes Care
  91. (2004). Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post-prandial glucose.
  92. (2008). Effects of intensive glucose lowering in type 2 diabetes.
  93. (2003). Efficacy of acarbose in Chinese subjects with impaired glucose tolerance.
  94. (2002). Elevated C-reactive protein values and atherosclerosis in sudden coronary death: Association with different pathologies. Circulation
  95. (2002). Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes
  96. (2000). Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.
  97. (2003). Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation
  98. (2001). Endocrine functions of the Pancreas and Regulation of Carbohydrate Metabolism.
  99. (2003). Endocrine pancreas functions.
  100. (2008). Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus.
  101. (2001). Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol
  102. (2005). Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem
  103. (1971). Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry
  104. (1971). Enzyme-linked immunosorbent assay. II. Quantitative assay of protein antigen, immunoglobulin G, by means of enzyme-labelled antigen and antibody-coated tubes. Biochim Biophys Acta
  105. (1972). Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem
  106. (2003). et al on behalf of, the EuropeanSociety of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement.
  107. (2002). Ethnic and socio-economic inequalities in coronary heart disease, diabetes and risk factors in Europeans and South Asians. J Public Health Med
  108. (2008). Ethnic differences in the relationship between adiponectin and insulin sensitivity in South Asian and Caucasian women. Diabetes Care
  109. (1997). Ethnicity and cardiovascular risk: variations in people of African ancestry and South Asian origin. J Hum Hypertens
  110. (1999). Evaluation of Precision performance of Clinical Chemistry Devces, Approved guideline.
  111. (2003). Evaluation of the Linearity of Quantitaive analytical Methods, Approved guideline.
  112. (1994). Evidence for impaired pancreatic beta cell function in South African Indians with impaired glucose tolerance. Dia Med
  113. (2006). Evidence of abnormal aortic compliance, an early manifestation of vascular disease,
  114. (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med
  115. (2007). Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 56(4):1153-9,
  116. (2003). Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metab
  117. (2005). Fat in the liver and insulin resistance. Ann Med
  118. (2006). Federation. IDF consensus: Worldwide definition of the metabolic syndrome.
  119. (2006). Federation. The IDF consensus world wide definition of the Metabolic syndrome.
  120. (1988). First-phase insulin response to glucose in nonobese or obese subjects with glucose intolerance: analysis by C-peptide secretion rate. Metabolism
  121. (2007). Fiveyear predictive factors of type 2 diabetes in men with impaired fasting glucose.
  122. (1998). Glucose intolerance and associated factors in the Fergana Valley, Uzbekistan. Diabet Med
  123. (1986). Glucose intolerance and hypertension in north London: the Islington Diabetes Survey. Diabet Med
  124. (1995). Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia
  125. (2004). Glucose intolerance and its relation to cardiovascular risk factors among Greenland Inuit. The Greenland Population Study. Int J Circumpolar Health
  126. (2001). Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med
  127. (1999). Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet
  128. (1992). Glucose toxicity. Endocr Rev
  129. (1995). Haemoglobin A(1c) measurement for diabetes among subjects with a previous history of impaired glucose tolerance. Diabetes Res Clin Pract
  130. (1988). Health and deprivation: inequalities and the north. Croom Helm,
  131. (1999). Health survey for England: the health of minority ethnic groups '99.
  132. (2006). Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes
  133. (2003). High prevalence of diabetes and impaired fasting glycaemia in urban Nepal. Diabet Med
  134. (2001). High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care
  135. (2007). High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 30(2):332-6,
  136. (1985). Homeostatic Model Assessment: insulin resistance and â-cell function from fasting plasma glucose and Insulin concentrations in man. Diabetologia
  137. (1987). Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes
  138. (1987). Hyperglycemia stimulates carbohydrate oxidation in humans.
  139. (2006). Hypovitaminosis D and risk of Type 2 diabetes in British South Asians. Diabet Med
  140. (2006). Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment.
  141. (2005). Hypovitaminosis D is associated with reductions in serum apolipoprotein A-I but not with fasting lipids in British Bangladeshis.
  142. (1983). Identification of underprivileged areas.
  143. (2005). Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care
  144. (2006). Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care
  145. (2005). Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care
  146. (1991). Impact of late complications in type 2 diabetes in a Dutch population. Diabet Med
  147. (2009). Impact of metabolic syndrome, diabetes and prediabetes on cardiovascular events: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract
  148. (1999). Impact of the 1997 American Diabetes Association criteria on classification of glucose intolerance among Kuwaitis below 50 years of age. Acta Diabetol
  149. (2002). Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance--is insulin resistance initiated in the adipose tissue? Int J Obes Relat Metab Disord
  150. (1997). Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance.
  151. (2007). Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care
  152. (2003). Impaired fasting glucose and risk of diabetes in Taiwan: follow-up over 3 years. Diabetes Res Clin Pract
  153. (1999). Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med
  154. (1999). Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care
  155. (2000). Impaired fasting glucose: how low should it go? Diabetes Care
  156. (2008). Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia
  157. (2000). Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med
  158. (2002). Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med
  159. (1999). Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care
  160. (1998). Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study.
  161. (2002). Impaired glucose tolerance: qualitative and quantitative study of general practitioners' knowledge and perceptions. BMJ
  162. (2002). Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance.[see comment]. Diabetes Care 25(9):1504-10,
  163. (1998). Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Br J Nutr
  164. (2007). Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet Med
  165. (1990). Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes
  166. (2004). Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension
  167. (2005). Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care
  168. (2006). Increased pulse wave velocity, a surrogate measure of arterial stiffness, in screen detected glucose intolerance. Diabetic Medicine 23[s 4],
  169. (2007). Index of multiple deprivation,
  170. (2003). Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation
  171. (2000). Inflammatory markers of coronary risk.
  172. (2005). Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury. Ann Surg
  173. (2002). Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol
  174. (2001). Insulin action in the vasculature: physiology and pathophysiology.
  175. (1979). Insulin deficiency and Insulin Resistance Interaction in Diabetes: Estimation of their relative contribution by feeback analysis from Basal Plasma Insulin and Glucose concentrations. Metabolism
  176. (1993). Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus. Diabet Med
  177. (2003). Insulin receptor signalling and regulation.
  178. (2005). Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. [Review] [75 refs].
  179. (2001). Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care
  180. (1993). Insulin resistance and insulin secretory dysfunction as precursors of non-insulindependent diabetes mellitus. Prospective studies of Pima Indians.
  181. (2003). Insulin resistance in Type 2 Diabetes.
  182. (2006). Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes
  183. (1998). Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia
  184. (1999). Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet
  185. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
  186. (2005). Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes
  187. (1994). Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men.
  188. Intimal media thickness, glucose intolerance and metabolic syndrome in Asian Indians-the Chennai Urban Rural Epidemiology Study
  189. (2004). Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med
  190. (2003). Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care
  191. (2009). Large-scale epidemiological data on cardiovascular diseases and diabetes in migrant and ethnic minority groups in Europe.
  192. (2006). Leicestershire ethnic data
  193. (2006). Linking inflammation and atherogenesis: Soluble markers identified for the detection of risk factors and for early risk assessment. Clin Chim Acta
  194. (1998). Long-term complications in newly diagnosed Sri Lankan patients with type 2 diabetes mellitus.
  195. (2005). Long-term nonpharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev
  196. (1989). Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res
  197. (2003). Longitudinal Study of Aging. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes
  198. (2005). Longterm effectiveness of weight-loss interventions in adults with pre-diabetes: a review.[erratum appears in Am J Prev Med.
  199. (2004). Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia
  200. (1987). Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes
  201. (1994). Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabet Med
  202. (1999). Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes
  203. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting.
  204. (1997). Meta-analysis: principles and procedures. BMJ
  205. (2008). Metab Syndr Relat Disord
  206. (2008). Metabolic characteristics of glucose intolerance: the critical role of obesity. Exp Clin Endocrinol Diabetes
  207. (1999). Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes
  208. (2001). Metabolic effects of metformin in patients with impaired glucose tolerance. Diabetic Medicine 18(7):578-83,
  209. (2002). Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect. Expert Opin Pharmacother
  210. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
  211. (2002). Method Comparison and Bias Estimation using Patient Samples, Approved guideline 2nd Edition,
  212. (1989). Methods and prevalence of non-insulin-dependent diabetes mellitus in a biethnic Colorado population. The San Luis Valley Diabetes Study.
  213. (1994). Microalbuminuria precedes the development of NIDDM. Diabetes
  214. (2007). Migration and its impact on adiposity and type 2 diabetes. Nutrition
  215. (2005). Molecular mechanisms of insulin resistance. Diabet Med
  216. (1990). Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study.
  217. (2003). National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med
  218. (2004). Nerve conduction abnormalities in different stages of glucose intolerance. Neurol India
  219. (1958). Nonparametric estimation from incomplete observations.
  220. (2005). Normal fasting plasma glucose levels and type 2 diabetes in young men.
  221. (1988). Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev
  222. (2006). Obesity and the role of adipose tissue in inflammation and metabolism.
  223. (2004). Obesity wars: Molecular progress confronts an expanding epidemic. Cell
  224. (2007). Office for National statistics. NOMIS population database (University of Durham).
  225. (1992). Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care
  226. (2006). PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol
  227. (1999). Pakistan National Diabetes Survey prevalence of glucose intolerance and associated factors in North West at Frontier Province (NWFP) of Pakistan. J Pak Med Assoc
  228. (1999). Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Baluchistan province. Diabetes Res Clin Pract
  229. (1995). Pakistan national diabetes survey: prevalence of glucose intolerance and associated factors in Shikarpur, Sindh Province. Diabet Med
  230. (2008). Paradigm Shift to the Integrative Big-Five Trait Taxonomy: History, Measurement, and Conceptual Issues. In:
  231. (1997). Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care
  232. (2004). Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109(18):2197-202,
  233. (2006). Persistent impaired glucose tolerance has similar rate of risk factors as for diabetes--results of Indian diabetes prevention programme (IDPP). Diabetes Res Clin Pract
  234. (2007). Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ
  235. (1997). Plasma glucose and prediction of microvascular disease and mortality: evaluation of
  236. (2007). Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol
  237. (2004). Populationbased stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia
  238. (2009). Position statement: Impaired glucose regulation (IGR)/ Nondiabetic hyperglycaemia (NDH)/ Prediabetes.
  239. (1999). Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.
  240. (2003). Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. [Review] [69 refs].
  241. Prediabetes and its relationship with obesity in Mexican adults: The Mexican Diabetes Prevention
  242. Predicting Impaired glucose toletance
  243. (2003). Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care
  244. (1997). Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes
  245. (2005). Presence of complications of diabetes in individual with screen-detected type 2 diabetes. Diabetic Medicine
  246. (1999). Prevalence and incidence of type-2 diabetes and impaired glucose tolerance in a selected Indian urban population.
  247. (1993). Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care
  248. (2006). Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002.[see comment].
  249. (1998). Prevalence of glucose intolerance among Native Hawaiians in two rural communities. Native Hawaiian Health Research (NHHR) Project. Diabetes Care
  250. (1997). Prevalence of glucose intolerance in urban and rural communities in Saudi Arabia. Diabet Med
  251. (2008). Prevalence of undiagnosed Type-2-diabetes mellitus and impaired fasting glucose
  252. (1997). Prevention Conference V: Beyond secondary prevention: identifying the high28,
  253. (2009). Prevention of diabetes self-management program (PREDIAS): effects on weight, metabolic risk factors, and behavioral outcomes. Diabetes Care
  254. (2005). Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.
  255. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.[see comment].
  256. (2004). Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet Med
  257. (1968). Principles and practice of screening for disease.
  258. (2006). Principles of Immunochemical techniques.
  259. (2007). Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark. Diabetologia
  260. (2007). Progression from newly acquired impaired fasting glusose to type 2 diabetes.[see comment]. Diabetes Care 30(2):228-33,
  261. (2006). Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation
  262. (1995). prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes
  263. (1986). Protocole de validation de techniques (document B). Annales de Biologie Clinique
  264. (1991). Public awareness of the symptoms of diabetes mellitus.
  265. (1999). Q3- Background, Q4-Objectives, Q5-Study design, Q6-Setting, Q7- Participants, Q8- Variables, Q9-Data sources, Q10- Bias, Q11- Study size, Q12- Quantitative variables,
  266. (1995). Random capillary whole blood glucose test as a screening test for diabetes mellitus in a middle-aged population.
  267. (2010). Rationale and design of the ADDITION-Leicester study, a systematic screening programme and Randomised Controlled Trial of multi-factorial cardiovascular risk intervention in people with Type 2 Diabetes Mellitus detected by screening. Trials
  268. (2008). Reasons or excuses for avoiding meta-analysis in forest plots. BMJ
  269. (1993). Recruitment methods for screening programmes: the price of high compliance. Health Econ
  270. (2006). REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet
  271. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
  272. (1998). Regional Office for Europe WHO. Use of Well-Being Measures in Primary Health Care - The DepCare Project. Health For All [Target 12].
  273. (2001). Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA
  274. (1999). Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol
  275. (2005). Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabetic Medicine 22(9):1263-6,
  276. (2004). Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Med Sci Sports Exerc
  277. Renal Association UK. Chronic kidney disease staging.
  278. (1985). Report of a WHO study group.
  279. (1985). Reproducibility of the new diagnostic criteria for impaired glucose tolerance.
  280. (2005). Retinopathy in persons with impaired glucose metabolism: the Australian Diabetes Obesity and Lifestyle (AusDiab) study.
  281. (2005). Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther
  282. (1992). Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.
  283. (1999). Screening for Type 2 diabetes mellitus in the UK Indo-Asian population. Diabet Med
  284. (2004). Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care
  285. (1995). Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract
  286. (1996). Serum immunoreactive-leptin concentrations in normal- weight and obese humans.
  287. (2008). Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology
  288. (1993). SF-36® Health Survey Manual and Interpretation Guide. Boston: The Health Institute,New England Medical Center,
  289. (2006). Societies. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91[Suppl 5],
  290. (1988). Spectrochemical Analysis.
  291. (1998). Spurious precision? Meta-analysis of observational studies.
  292. (2002). Statistical methods for Psychology. 5 ed.
  293. (1996). Statistics in epidemiology: methods techniques and applications.
  294. (2006). Strategies for the early detection of type 2 diabetes in an at risk population.
  295. (2010). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).
  296. (1991). Study design, progress and performance. Diabetologia
  297. (1991). Study in Tanzania of impaired glucose tolerance. Methodological myth? Diabetes
  298. (2008). Systematic review on the prevalence of diabetes, overweight/obesity and physical inactivity in Ghanaians and Nigerians. Public Health
  299. (2004). Targeted screening for undiagnosed diabetes reduces the number of diagnostic tests. Inter99(8). Diabet Med
  300. (2008). The accuracy of self-measurement and self-estimation of waist circumference in a multi-ethnic population. Diabet Med
  301. (2000). The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening.
  302. (2009). The ADDITION-Cambridge trial protocol: a cluster --randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health
  303. (2003). The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology
  304. (2003). The anatomy, organisation and ultrastructure of the islets of Langerhans.
  305. (1991). The Big Five Inventory--Versions 4a and 54.
  306. (2003). The biosyntheis and secretion of Insulin. In:
  307. (2005). The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med
  308. (1991). The Coventry Diabetes Study: prevalence of diabetes and impaired glucose tolerance in Europids and Asians.
  309. (2003). The Diabetes Risk Score.
  310. (1993). The early identification and aetiology of glucose intolerance.
  311. (2005). The effect of defective early phase insulin secretion on postload glucose intolerance in impaired fasting glucose. Endocr J
  312. (2001). The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
  313. (2006). The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf)
  314. (2004). The English Indices of Deprivation
  315. (2003). The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care
  316. (1997). The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial. Metabolism
  317. (1992). The growing prevalence of non-insulin-dependent diabetes in migrant Asian populations and its implications for Asia. Diabetes Res Clin Pract
  318. (1982). The high prevalence of diabetes mellitus, impaired glucose tolerance and diabetic retinopathy in Nauru--the
  319. (1989). The impact of confounder selection criteria on effect estimation.
  320. (2006). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia
  321. (2004). The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity. J Am Soc Nephrol
  322. (2003). The insulin resistance syndrome.
  323. (2006). The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr
  324. (2004). The interplay of cardiovascular risk factors in the metabolic syndrome and type 2 diabetes.
  325. (1994). The IQOLA Project Group. The SF-36® Health Survey: development and use in mental health research and the IQOLA Project.
  326. (2010). The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabet Med
  327. (2008). The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet
  328. (1982). The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement.
  329. (1999). The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.
  330. The new classification of diabetes mellitus and IGT: a critical approach. Exp Clin Endocrinol Diabetes 2001; 109 Suppl 2:S86-S93.
  331. (2010). The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting Type 2 diabetes mellitus. Diabet Med
  332. (1985). The prevalence of diabetes mellitus in a large group of South African Indians.
  333. (1999). The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome.
  334. (2005). The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care
  335. (2008). The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes.
  336. (1999). The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care
  337. (2002). The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care
  338. (1983). The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care
  339. (2001). The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia
  340. (2007). The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia
  341. (2007). The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. [Review] [124 refs].
  342. (1985). The Southall Diabetes Survey: prevalence of known diabetes in Asians and Europeans.
  343. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet
  344. (2003). The structure and phylogeny of Insulin. In:
  345. (2006). The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia
  346. (1998). Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab Rev
  347. (2007). Transient and persistent impaired glucose tolerance and progression to diabetes in South Asians and Europeans: new, large studies are a priority. Diabet Med
  348. (1988). Transient impaired glucose tolerance in Pima Indians: is it important? BMJ
  349. (2000). Type 2 diabetes mellitus, impaired glucose tolerance and associated factors in a rural Palestinian village. Diabetic Medicine 17(10):746-8,
  350. (2007). UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet
  351. (1984). Underprivileged areas: validation and distribution of scores.
  352. (2005). Undiagnosed diabetes in 2 Eeyou Istchee (Eastern James Bay Cree) communities: A population-based screening project.
  353. (1995). Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med
  354. (2006). Use and abuse of HOMA Modeling. Diabetes Care
  355. (2011). Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation.
  356. (1998). Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. Diabetes Care
  357. (1995). Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA
  358. (2009). Validation of an algorithm combining haemoglobin A(1c) and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations. Diabet Med
  359. (2001). Validity of the five-item WHO Well-Being Index (WHO-5) in an elderly population. Eur Arch Psychiatry Clin Neurosci
  360. (2006). Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol
  361. (1998). Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ
  362. (2007). Vitamin D and vascular calcification. Curr Opin Lipidol
  363. (2008). Vitamin D deficiency and risk of cardiovascular disease. Circulation
  364. (2008). Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med
  365. (1995). Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men.
  366. (1998). Vitamin D replacement in Asians with diabetes may increase insulin resistance. Postgrad Med J
  367. (1999). von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol
  368. (2008). Waiting for diabetes: perceptions of people with pre-diabetes: a qualitative study. Patient Educ Couns
  369. (2004). What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care
  370. (1996). Why we need observational studies to evaluate the effectiveness of health care.
  371. (1998). Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.